Shenzhen Kangtai Biological Products (300601.SZ): Tetanus vaccine receives drug registration certificate

Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biological Technology Co., Ltd. (referred to as "Minhai Biology"), has received the "Drug Registration Certificate" issued by the National Medical Products Administration today for the adsorbed tetanus vaccine developed by Minhai Biology. The adsorbed tetanus vaccine is a vaccine prepared by adsorbing tetanus toxin with an adjuvant. This vaccine is mainly used for populations with a higher risk of traumatic injuries, and vaccination of pregnant women with this product can prevent tetanus in mothers and newborns. After vaccination with this vaccine, the body can produce tetanus antibodies to prevent tetanus. Tetanus is an extremely serious acute infectious disease caused by the growth and reproduction of Clostridium tetani bacteria in the local wound area and the production of toxins after invading the human body through skin or mucous membrane wounds.